Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Scott M. Schuetze(University of Michigan), Maria Dêbiec‐Rychter(Center for Human Genetics), Dolores López‐Terrada(Baylor College of Medicine), Hans Gelderblom(Leiden University Medical Center), Peter Hohenberger(University of Mannheim), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Raf Sciot(KU Leuven), M. van Glabbeke(Institut Jules Bordet), Allan T. van Oosterom(Cleveland Clinic), Brian P. Rubin(Cleveland Clinic), W. Ruka(Cleveland Clinic), Cathryn Rankin(Cleveland Clinic)
Cited by 401
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Cremophor EL
|European Journal of Cancer|2001|1.6k